A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
|Study Design:||Endpoint Classification: Pharmacokinetics Study
Primary Purpose: Treatment
|Official Title:||A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.|